glp 1 agonist medicine How GLP-1 medications are transforming diabetes and weight loss treatment Discovery of GLP-1–Based Drugs for

both produce large, clinically meaningful weight loss in human trials

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

To understand why these therapies have attracted attention in longevity research, it is useful to first examine the scientific framework that describes the biological processes underlying aging

However, this situation has changed dramatically with emerging evidence highlighting the metabolic benefits of dual GLP-1 receptor (GLP-1R) and GIPR agonists

According to the literature addressing clinical trials, GI AEs usually develop in 4070% of treated patients, although they have sometimes been reported in up to 85% [9,10,11,12,13,14,15,16,17]